Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 20/20 | 0.76 |
| ▸ | CHRNA1 | P02708 | 6/20 | 0.76 |
| ▸ | CHRNG | P07510 | 6/20 | 0.76 |
| ▸ | CHRNB1 | P11230 | 6/20 | 0.76 |
| ▸ | CHRNB2 | P17787 | 6/20 | 0.76 |
| ▸ | CHRNB4 | P30926 | 6/20 | 0.76 |
| ▸ | CHRNA3 | P32297 | 6/20 | 0.76 |
| ▸ | CHRNA4 | P43681 | 6/20 | 0.76 |
| ▸ | CHRND | Q07001 | 6/20 | 0.76 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.76 |
| ▸ | HTR3A | P46098 | 5/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3149673 | 0.88 | CHRNA7 (0.78) | CHRNA7CHRNA1CHRNGCHRNB1CHRNB2 | |
| SCHEMBL3150145 | 0.88 | CHRNA7 (0.78) | CHRNA7CHRNA1CHRNGCHRNB1CHRNB2 | |
| Hydrochloric Acid SCHEMBL3148820 | 0.87 | CHRNA7 (0.76) | CHRNA7CHRNA1CHRNGCHRNB1CHRNB2 | |
| Hydrochloric Acid SCHEMBL3148810 | 0.87 | CHRNA7 (0.76) | CHRNA7CHRNA1CHRNGCHRNB1CHRNB2 | |
| SCHEMBL1956481 | 0.87 | CHRNA7 (1.00) | CHRNA7CHRNA1CHRNGCHRNB1CHRNB2 | |
| SCHEMBL3152735 | 0.87 | CHRNA7 (1.00) | CHRNA7CHRNA1CHRNGCHRNB1CHRNB2 | |
| SCHEMBL3152748 | 0.87 | CHRNA7 (1.00) | CHRNA7CHRNA1CHRNGCHRNB1CHRNB2 | |
| Hydrochloric Acid SCHEMBL3154761 | 0.85 | CHRNA7 (0.98) | CHRNA7CHRNA1CHRNGCHRNB1CHRNB2 | |
| Hydrochloric Acid SCHEMBL3154747 | 0.85 | CHRNA7 (0.98) | CHRNA7CHRNA1CHRNGCHRNB1CHRNB2 | |
| SCHEMBL3143072 | 0.78 | CHRNA7 (1.00) | CHRNA7CHRNA1CHRNGCHRNB1CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210338621-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | NOVARTIS AG (CH) | 2021-11-04 | — | — | US | disclosed |
| US-20200108035-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | NOVARTIS AG (CH) | 2020-04-09 | — | — | US | disclosed |
| EP-2959902-A1 | USE OF AZABICYCLOALKYL DERIVATIVES FOR THE TREATMENT OR PREVENTION OF ATAXIA | Novartis AG (CH) | 2015-12-30 | — | — | EP | disclosed |
| US-20140171448-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | NOVARTIS AG (CH) | 2014-06-19 | — | — | US | disclosed |
| EP-2480228-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | Novartis AG (CH) | 2012-08-01 | — | — | EP | disclosed |
| US-20120172346-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | NOVARTIS AG | 2012-07-05 | — | — | US | disclosed |
| US-20120157464-A1 | USE OF AZABICYCLOALKYL DERIVATIVES OR PYRROLIDINE-2-ONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF ATAXIA | NOVARTIS AG | 2012-06-21 | — | — | US | disclosed |
| EP-2456438-A2 | USE OF AZABICYCLOALKYL DERIVATIVES OR PYRROLIDINE-2-ONE DERIVATIVES | Novartis AG (CH) | 2012-05-30 | — | — | EP | disclosed |
| EP-2332537-A1 | Combinations of nicotinic acetylcholine alpha 7 receptor agonists | Novartis AG (CH) | 2011-06-15 | — | — | EP | disclosed |
| WO-2011036167-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | NOVARTIS AG (CH) | 2011-03-31 | — | — | WO | disclosed |
| US-20100125063-A1 | COMBINATIONS OF NICOTINIC ACETYLCHOLINE ALPHA 7 RECEPTOR AGONISTS | NOVARTIS AG | 2010-05-20 | — | — | US | disclosed |
| EP-2135609-A1 | Combinations of nicotinic acetylcholine alpha 7 receptor agonists | Novartis AG (CH) | 2009-12-23 | — | — | EP | disclosed |
| US-20080306081-A1 | Combinations of Nicotinic Acetylcholine Alpha 7 Receptor Antagonists | NOVARTIS AG (CH) | 2008-12-11 | — | — | US | disclosed |
| EP-1809285-A1 | COMBINATIONS OF NICOTINIC ACETYLCHOLINE ALPHA 7 RECEPTOR AGONISTS | Novartis AG (CH) | 2007-07-25 | — | — | EP | disclosed |
| WO-2006048294-A1 | COMBINATIONS OF NICOTINIC ACETYLCHOLINE ALPHA 7 RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2006-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171448-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | CHRNA7, CHRNG, CHRNA6 | CHRNA7 1/4885CHRNA1 4/4885CHRNG 2/4885 |
| US-20120172346-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | CHRNA7, CHRNA5, CHRNA4 | CHRNA7 1/4885CHRNA1 9/4885CHRNG 4/4885 |
| US-20100125063-A1 | COMBINATIONS OF NICOTINIC ACETYLCHOLINE ALPHA 7 RECEPTOR AGONISTS | CHRNA7, CHRNA4, CHRNA10 | CHRNA7 1/4885CHRNA1 7/4885CHRNG 16/4885 |
| US-20200108035-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | CHRNA7, CHRNA5, CHRNA4 | CHRNA7 1/4885CHRNA1 9/4885CHRNG 4/4885 |
| US-20080306081-A1 | Combinations of Nicotinic Acetylcholine Alpha 7 Receptor Antagonists | CHRNA7, CHRNA4, CHRNA10 | CHRNA7 1/4885CHRNA1 7/4885CHRNG 16/4885 |
| US-20120157464-A1 | USE OF AZABICYCLOALKYL DERIVATIVES OR PYRROLIDINE-2-ONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF ATAXIA | ATXN2, CDR2, ATXN2L | CHRNA7 205/4885CHRNA1 1288/4885CHRNG 1468/4885 |
| US-20210338621-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | CHRNA7, CHRNA5, CHRNA4 | CHRNA7 1/4885CHRNA1 9/4885CHRNG 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.